---
title: "Artivion, Inc. (AORT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AORT.US.md"
symbol: "AORT.US"
name: "Artivion, Inc."
industry: "Health Care Equipment"
datetime: "2026-05-21T03:03:52.797Z"
locales:
  - [en](https://longbridge.com/en/quote/AORT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AORT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AORT.US.md)
---

# Artivion, Inc. (AORT.US)

## Company Overview

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [artivion.com](https://artivion.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: B (0.35)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 26 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 17.59% |  |
| Net Profit YoY | 154.69% |  |
| P/B Ratio | 2.45 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1103390345.50 |  |
| Revenue | 458689000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.14% | C |
| Profit Margin | 2.55% | C |
| Gross Margin | 64.85% | A |
| Revenue YoY | 17.59% | B |
| Net Profit YoY | 154.69% | A |
| Total Assets YoY | 11.63% | B |
| Net Assets YoY | 53.09% | A |
| Cash Flow Margin | 496.59% | A |
| OCF YoY | 17.59% | B |
| Turnover | 0.55 | C |
| Gearing Ratio | 48.99% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Artivion, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "17.59%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "154.69%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.45",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1103390345.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "458689000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.14%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "2.55%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "64.85%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "17.59%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "154.69%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "11.63%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "53.09%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "496.59%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "17.59%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "48.99%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 94.24 | 43/183 | 186.24 | 179.23 | 172.17 |
| PB | 2.44 | 65/183 | 4.94 | 4.67 | 4.01 |
| PS (TTM) | 2.40 | 58/183 | 5.06 | 4.49 | 3.74 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-20T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 86% |
| Overweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 22.67 |
| Highest Target | 58.00 |
| Lowest Target | 42.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AORT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AORT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AORT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AORT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**